Protein formulations and methods of making same
The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
1. An aqueous pharmaceutical formulation comprising:
(a) an anti-tumor necrosis factor alpha antibody comprising a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7, and a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, wherein the concentration of the antibody is 50 to 200 mg/ml;
(b) from 10-50 mM NaCl;
(c) a surfactant;
(d) a polyol; and
(e) water;
wherein the formulation does not comprise a buffering system, and
wherein the pH of the formulation is from 4 to 8.
2. The formulation of claim 1 , wherein the surfactant is a non-ionic surfactant.
3. The formulation of claim 2 , wherein the surfactant is a polysorbate.
4. The formulation of claim 3 , wherein the surfactant is polysorbate-20 or polysorbate-80.
5. The formulation of claim 1 , wherein the polyol is a sugar or sugar alcohol.
6. The formulation of claim 5 , wherein the polyol is sucrose or mannitol.
7. The formulation of claim 1 , wherein the surfactant is a non-ionic surfactant, and wherein the polyol is a sugar or sugar alcohol.
8. The formulation of claim 7 , wherein the surfactant is a polysorbate.
9. The formulation of claim 8 , wherein the surfactant is polysorbate-20 or polysorbate-80.
10. The formulation of claim 7 , wherein the polyol is sucrose or mannitol.
11. The formulation of claim 8 , wherein the polyol is sucrose or mannitol.
12. The formulation of claim 9 , wherein the polyol is sucrose or mannitol.
13. An aqueous pharmaceutical formulation comprising:
(a) 100 mg/ml adalimumab;
(b) from 10-50 mM NaCl;
(c) a polysorbate;
(d) a polyol, wherein the polyol is sucrose or mannitol; and
(e) water;
wherein the formulation does not comprise a buffering system, and
wherein the pH of the formulation is from 4 to 8.
14. The formulation of claim 13 , wherein the polysorbate is polysorbate-20 or polysorbate-80.
15. An aqueous pharmaceutical formulation comprising:
(a) 100 mg/ml adalimumab;
(b) from 10-50 mM NaCl;
(c) polysorbate-80;
(d) a polyol, wherein the polyol is sucrose or mannitol; and
(e) water;
wherein the formulation does not comprise a buffering system, and
wherein the pH of the formulation is from 4 to 6.
16. The formulation of claim 15 , wherein the pH is from 5 to 6.
17. The formulation of claim 15 , wherein the polyol is sucrose.
18. The formulation of claim 15 , wherein the polyol is mannitol.
19. The formulation of claim 16 , wherein the polyol is sucrose.
20. The formulation of claim 16 , wherein the polyol is mannitol.